Cargando…
The Therapeutic Potential of AN-7, a Novel Histone Deacetylase Inhibitor, for Treatment of Mycosis Fungoides/Sezary Syndrome Alone or with Doxorubicin
The 2 histone deacetylase inhibitors (HDACIs) approved for the treatment of cutaneous T-cell lymphoma (CTCL) including mycosis fungoides/sezary syndrome (MF/SS), suberoylanilide hydroxamic acid (SAHA) and romidepsin, are associated with low rates of overall response and high rates of adverse effects...
Autores principales: | Moyal, Lilach, Feldbaum, Nataly, Goldfeiz, Neta, Rephaeli, Ada, Nudelman, Abraham, Weitman, Michal, Tarasenko, Nataly, Gorovitz, Batia, Maron, Leah, Yehezkel, Shiran, Amitay-Laish, Iris, Lubin, Ido, Hodak, Emmilia |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4709199/ https://www.ncbi.nlm.nih.gov/pubmed/26752418 http://dx.doi.org/10.1371/journal.pone.0146115 |
Ejemplares similares
-
Stage-dependent Increase in Expression of miR-155 and Ki-67 and Number of Tumour-associated Inflammatory Cells in Folliculotropic Mycosis Fungoides
por: ATZMONY, Lihi, et al.
Publicado: (2020) -
mAb14, a Monoclonal Antibody against Cell Surface PCNA: A Potential Tool for Sezary Syndrome Diagnosis and Targeted Immunotherapy
por: Knaneh, Jamal, et al.
Publicado: (2023) -
Mycosis fungoides and Sézary syndrome
por: Jonak, Constanze, et al.
Publicado: (2021) -
Mycosis fungoides and Sézary syndrome
por: Lee, Hyewon
Publicado: (2023) -
Melanoma Risk is Increased in Patients with Mycosis Fungoides Compared with Patients with Psoriasis and the General Population
por: SHERMAN, Shany, et al.
Publicado: (2020)